Navigation Links
Effective Treatment Option For Macular Degeneration

The wet form of macular degeneration represents about 10 percent of the overall disease prevalence. Age-related macular degeneration is the leading cause of irreversible, severe vision loss in people 50 years of age and older. // Two new studies show a therapy known as pegaptanib (Macugen) is an effective treatment for age-related, "wet" macular degeneration.

The trials were conducted at 117 centers in the United States, Canada, Europe, Israel, Australia and South America and a total of 1,208 patients were involved in the study. The participants received either 0.3 milligrams of pegaptanib, 1.0 milligrams of pegaptanib, 3.0 milligrams of pegaptanib, or a placebo.

Researchers observed a significant difference in patients who received the pegaptanib as early as six weeks after the treatment was given. The maximum benefit was observed after 54 weeks of treatment. Pegaptanib also reduced the chance of the loss of 15 letters or more of visual acuity, which is considered a moderate loss. It also reduced the chance of the loss of 30 letters or more (six lines on the eye chart), which is considered a severe loss.

Thus researchers say treatment with pegaptanib reduced the risk of progression to legal blindness in the study, promoted stability of vision, and in a small percentage of patients, resulted in more visual improvement at week 54 than among those receiving sham injections.
'"/>




Page: 1

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 2016 , ... Compliancy Group LLC is pleased to offer ... the country. The Guard was specifically designed to handle each element required for ... updates, and compliance coaching. , In addition to meeting the compliance needs of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize ... can leave patients with dental emergencies at risk of losing a tooth or their ... care. , Common dental emergencies include:, , Avulsed or ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... Indianapolis, IN (PRWEB) , ... February 10, 2016 ... ... employee benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its ... and has seven other locations throughout the Southeast, from Orlando to Huntsville and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology: